Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Discontinued
Reference number: GID-TA11020
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer have been revised. It is anticipated that the appraisal will begin in early-October 2023 when we will write to you about how you can get involved.